Pharma News

Granules India ltd has received a license from Medicines Patent Pool (MPP) to manufacture and market generic versions of Pfizer’s oral treatment nirmatrelvir which will be copackaged with ritonavir for treatment of COVID-19. The licenses are applicable for both active pharmaceutical ingredients (API) and finished products, in tablet form, of nirmatrelvir; ritonavir.

Granules India Limited, announced that Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of the company, located in Chantilly, Virginia, USA received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA).

The GPI facility was inspected by the US FDA from 24th to 28th January 2022 for two of its product applications filed. There were three minor observations during the inspection and GPI had addressed the observations in the stipulated time period.

A new survey from Sermo, a physician-first online community and leader in global HCP insights, found that physicians are facing a challenging onslaught of COVID-19 vaccine and treatment misinformation as reported by 3,600+ doctors around the world.

Indian pharmaceutical companies may replace western manufacturers leaving the Russian market, Russian envoy to India Denis Alipov said.

"The withdrawal of many Western companies from the Russian market and those niches that have been vacated may actually be occupied by Indian companies in many industries, in particular, in pharmaceuticals," Alipov told the Rossiya 24 broadcaster, as quoted by Sputnik news agency.

To quote veteran science writer Ed Yong’s simple yet extremely accurate words in The Atlantic, “The immune system is very complicated.” As the COVID-19 pandemic had made abundantly clear, science still doesn’t fully understand the sophisticated defense mechanisms that protect us from microbe invaders. Why do some people show no symptoms when infected with SARS-CoV-2 while others suffer from severe fevers and body aches? Why do some succumb to cytokine storms of the body’s own making? We still lack exact answers to these questions.

A Johns Hopkins Children’s Center-led study in animals suggests that high doses of a widely used antibiotic called rifampin may safely treat and reduce the duration of treatment for the deadliest form of tuberculosis that affects the brain, potentially improving survival rates for patients and decreasing the likelihood of lasting adverse effects of the disease.

The Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers has released on its website, an Approach Paper for the Draft National Policy for the Medical Devices, 2022, inviting feedback and remarks of the Industry and stakeholders, till the 25th of March 2022.  In line with the mandate of promoting aspects of the medical device industry, the Department of Pharmaceuticals, realising the need to have a holistic policy to accelerate growth and explore the potential of the Medical Devices Sector, has published thiz approach paper, after extensi

Zydus Lifesciences Ltd has received final approval from the USFDA to market Colestipol Hydrochloride Tablets in the strength of 1mg (US RLD: Colestid). Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet.

Colestipol Hydrochloride is a highly complex macro molecule drug substance with little or no systemic absorption.

The SMILE-100 System is a breast thermography device that helps healthcare personnel to review, measure and analyse thermally significant indications in the breast region